Capricor plummets after FDA flags concerns over its Duchenne therapy
27/07/2026 13:49
BUZZ-Capricor plummets after FDA flags concerns over its Duchenne therapy ** Shares of drug developer Capricor Therapeutics CAPR.O, RIC shares fall 69.2% to $6.06 in premarket trading
** U.S. FDA staff reviewers raised concerns about whether co's cell therapy, deramiocel, has sufficient evidence of effectiveness for treating cardiomyopathy in Duchenne muscular dystrophy
** FDA last year declined to approve the muscle disorder drug, citing lack of efficacy data
** Capricor said in December that in a late-stage trial deramiocel significantly slowed the decline in muscle and heart function in patients compared with placebo
** Duchenne muscular dystrophy is a genetic disease that weakens muscles and affects the heart
** Up to last close, stock has fallen 31.7% YTD
(Reporting by Sneha S K)